Opiate/Oxycodone Screen With Reflex Confirmation, Whole Blood
Use
This test is used to screen for the presence of opiates and oxycodone in whole blood. It serves as an initial presumptive test using immunoassay techniques, with any presumptive positives being confirmed through chromatography mass spectrometry (GC/MS or LC/MS-MS). The purpose of this test is to accurately detect opiate and oxycodone use, aiding in patient management and treatment monitoring for substance abuse.
Special Instructions
The test involves initial presumptive testing via immunoassay, followed by reflex confirmatory testing for any positive results. Healthcare providers should be aware of the reflex testing protocol and ensure specimen collection meets the standard requirements for volume and container type.
Limitations
The test has not been cleared or approved by the FDA, and its performance characteristics were determined by LabCorp. External factors or improper specimen handling might impact test accuracy. The use of immunoassay may result in false positives or negatives, necessitating confirmatory testing for definitive results.
Methodology
Immunoassay (Multiplex Protein Panel)
Biomarkers
LOINC Codes
- 51691-4
- 72402-1
- 51691-4
- 72402-1
- 34177-6
- 86226-8
- 74131-4
- 74130-6
- 86229-2
- 86230-0
- 86227-6
- 77731-8
- 77730-0
- 77729-2
Result Turnaround Time
4-10 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
7 mL
Minimum Volume
3 mL
Container
Gray-top (sodium fluoride/potassium oxalate) tube, green-top (heparin) tube, or lavender-top (EDTA) tube
Storage Instructions
Submission/transport (<3 days): Room temperature. For storage beyond three days, specimen should be refrigerated or frozen.